					PAGE	1	OF	_1	
Form PTO-1449			ment of Commerce	ATTY. DOCKET NO.		SERIAL N	0, 0		
(Rev. 7-80)		Patent and	d Trademark Office	33700W003		To Be Assig	med a		
There are the second	N DIGGI	OCUPE CEA	APPLICANT	•		866			
INFORMATIO	N DISCL	OSURE STA	TEMENT	Scott D. Wilbur et al.		<del></del>	⊃ <u></u>	9	
,	**	:6		FILING DATE		GROUP	252		
(	Use several sheet	s if necessary)		Herewith 3/6/00		1619	90	0	
		1	U.S. PATEN	T DOCUMENTS				=	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING I APPROF		
	AA	5,134,071	7/92	Gaetjens	435	188			
	AB	5,310,916	5/94	Jacobson et al.	546	224			
	AC								
	AD				ļ <u> </u>				
	AE				ļ				
	AF				<u> </u>				
	AG								
	AH				ļ				
	AI								
	AJ								
	AK				<u> </u>				
	AL				<u> </u>				
		FO]	REIGN PAT	TENT DOCUMENTS	,	т т			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS -	TRANSL	ATION NO	
LQV	AM	WO 89/10140	11/89	PCT					
1.	AN	WO 97/29114	8/97	PCT					
	AO	WO 93/02105	2/93	PCT		_			
, 5W	AP	0 310 361	4/89	EPO					
	AQ	0 618 192 A1	10/94	EPO					
	AR	WO 00702050	01/00	PCT					
	AS	-W <del>O</del> -96/04313	-02/96	PET			1		
	C	THER INFO	RMATION	(including author, title, date, pertin	nent pages, et	tc.)		N. Strange Mark	
	AT	Immunotargeting of antioxidant enzymes to the pulmonary endothelium, Proc. Natl Acad. Sci. USA, Vol. 93, pp. 5213-5218, May 1996							
	AU	PCT Request Form 101, and PCT Form 308 for above-noted WO 00/02050 PCT Publication							
AV American Chemical Society, copyright 1998, page 1									
EXAMINER				DATE CONSIDERED					
Sun C) Weld				1/8/01					
* Examiner: Initial if refe			n is in conformance	with MPEP 609; Draw line through ci	itation if not i	n conformance a	nd not considere	ed, include	



					PAGE	1	OF	4
Form PTO-144 (Rev. 7-80)	orm P10-1449 0.5. Department of Commerce   022700.000			ATTY. DOCKET NO. 033700.003 09/519,998			(O.	
				APPLICANT Wilber, et al	\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \	The Salar	T.	<b>`</b>
	(Use se	everal sheets if necessary)		FILING DATE March 6, 2000	GROUP (), 1616 1619			
		U.S	. PATENT DO	CUMENTS	·	EG.		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		DATE IF
LQW	Y	5,134,071	07/1992	Gaetjens				
ran	Z	5,310,916	05/1994	Jacobson, et al.				
		FORE	I IGN PATENT	DOCUMENTS	<u> </u>	<u> </u>	L	
					CLASS	SUBCLASS	TRANS	SLATION
	1	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
Law	AA	WO 96/04313	02/1996	WIPO				
	AB_	EP 618-192-A1	10/1994	EPO				X
LQW	AC	EP 310 361 A2	04/1989	EPO				
	AD	WO 93/02105	02/1993	WIPO				
	AE	WO 97/29114	08/1997	WIPO			1	
LOW	AF	WO 89/10140	11/1989	WIPO				
			<u> </u>			<del></del>		
	O'	THER INFORMATION	(including aut	hor, title, date, perti	nent pag	es, etc.)	1.6	
LQW	AG	"Immunotargeting of antioxidal., featured in <i>Proc. Natl. Acc</i>	ad. Sci.USA, Vol.	93, May 1996, pp. 5213-5	218			
	АН	"Development of a Streptavidi Method for Radioimmunother authored by Robert M. Sharke	rapy of Colorectal ( ey, et al., featured i	Cancer. Studies in a Hum n <i>Bioconjugate Chem.</i> , Vo	an Colon Col. 8, No. 4	Cancer Xenogr , 1997, pp. 59	aft Mode 5-604	l,"
	AI	"Rapid Blood Clearance of Bi featured in <i>The Journal of Nu</i>	clear Medicine, V	ol. 30, No. 1, January, 19	89, pp. 66-	69		
	AJ	"Galactosylated streptavidin for antibody," authored by D. Ma	rshall, et al., featu	red in <i>British Journal of C</i>	Cancer, Vo	l. 71, 199 <u>5,</u> pp	o. 18-24	
	AK	"The Role of Surface Carbohy authored by Gilbert Ashwell,	et al., featured in A	1dv. Enzymol, Vol. 41,197	<b>4</b> , pp. 99-1	128. (Ref Miss	ing)	
	AL	"Strategies to Enhance the Log featured in Current Medicinal	l Chemistry, Vol. :	2, 1995, pp. 616-629				
2aW	AM	"Improved Monoclonal Antib Henry, et al., featured in <i>Nucl.</i>	ody Tumor/Backg . <i>Med. Biol. Vol. 1</i>	round Ratios with Exchan 8, No. 5, 1991, pp. 565-50	57			nsune A.
EXAMINER	D auran	G. Wello			DATE	CONSIDER	ED	
* Examiner: Initia	al if referen	oce considered, whether or not citation of this form with next communication	on is in conformance	with MPEP 609; Draw line t	hrough citat	/ / • /	formance a	and not
	1.7							

				. <u> </u>	PAGE	<u>2</u>	OF <u>4</u>	
Enrm P111-1449 U.S. Department of Commerce			ATTY. DOCKET NO. SERIAL NO.					
<b>A</b>	kev. 7-80) Patent and Trademark Office							
101. 7 00)				APPLICANT				
<b>▼</b> INFORM	ATION	N DISCLOSURE STATEM	MENT	Wilber, et al				
				FILING DATE	_	GROUP	Y.	
(	(Use sev	veral sheets if necessary)		March 6, 2000	120	16167 lb	9	
		U.S.	PATENT DO	OCUMENTS	70	in to	0	
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
INITIAL					PE	2800	111110111111	
				/c	51 - Vig	- %		
				<del>                                     </del>		7		
					MAL 5 MAL	12		
				\ <u>\$</u>	JAN	7		
				<b>*</b>	(2)	<del></del>		
					Ce BADELLES			
		FOREI	GN PATENT	DOCUMENTS	<del></del>	1	TD ANGLATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES NO	
_								
						-		
						<u> </u>		
	<b>O</b> 7	THER INFORMATION (	including au	thor, title, date, p	ertinent pag	es, etc.)	1 4 (1 1	
		"Improved Tumor Imaging wit with Anti-antibody Column," a	h Radiolabeled	Monoclonal Antibodie	es by Plasma Cle	earance of Unb	ound Antibody	
LQW	AN	with Anti-antibody Column," a 512	uthored by Jame	es L. Lear, MID, et al.,	leatured in Kaa	iology, voi. 17	), 1))1, pp. 50)	
		"Radioimmunoadsorption of K	C-4G3 Antibod	y in Peripheral Blood:	Implications for	r Radioimmune	otherapy,"	
	AO	"Radioimmunoadsorption of KC-4G3 Antibody in Peripheral Blood: Implications for Radioimmunotherapy," authored by Timothy K. Johnson, et al., featured in Antibody, Immunoconjugates, and Radiopharmaceuticals, Vol.						
		4, No. 4, 1991, pp. 885-893						
	, ,	"Extracorporeal Immunoadsorp Radioactivity and Its Potential	otion of Radiolal	beled Monoclonal Ant	ibody: A metho	a ior Keaucuoi thored by Davi	d G Dienhart et	
	AP	al., featured in Antibody, Immu	noconjugates, a	md Radiopharmaceut	icals, Vol. 7, No	o. 4, 1994, pp.	225-252	
	4.0	"Immunoadsorption: An Enhan	ncement Strategy	y for Radioimmunothe	rapy," authored	by Gerald L. I	DeNardo, et al.,	
	AQ	featured in The Journal of Nuc	lear Medicine, `	Vol. 34, No. 6, June, 1	1993, pp. 1020-1	1027		
		"Biotin Reagents for Antibody	Pretargeting. S	ynthesis, Radioiodinat	tion, and in Vitr	o Evaluation of	t Water Soluble,	
	AR	Biotinidase Resistant Biotin De 8, 1997, pp. 572-584	envauves, aut	noted by D. Scott Will	our, et al., leatul	ca m <i>bioconju</i>	gaie Chem., vol.	
		"A General, Extracorporeal Im	munoadsorption	Method to Increase th	he Tumor-to-No	rmal Tissue Ta	rio in	
1	AS	Radioimmunoimaging and Rad	dioimmunothera	py," authored by Kris	tina Norrgren, e	t al., featured in	n The Journal of	
		Nuclear Medicine, Vol. 34, No.	o. 3, March, 199	3, pp. 448-454		of Ladin = 106 l	Labolad DD06	
	ATE	"Extracorporeal Whole-Blood Biotin Monoclonal Antibody,"	Immunoadsorpti	ion Enhances Kadioim iel Garkavii, et al. fea	munotargeting tured in <i>The Io</i> r	or rodine-125-l urnal of Nuclei	caveled BK90- ar Medicine. Vol.	
18/4/	AT	38, No. 6, June, 1997, pp. 895		ioi Gaikavij, oi ai., ica				
EXAMINER		,			DATE	CONSIDER	ED	
	Laure	n D Welle				6/8/	61	
<u> </u>		ce considered, whether or not citation	n is in conforman	e with MPFP 609. Draw	line through citat			
<ul> <li>Examiner: Initial considered, inclu</li> </ul>	ı ii reteren de copy of	ce considered, whether or not citation this form with next communication	to applicant.	will fai bi ooz, bian				

		······································			PAGE	3	OF <u>4</u>		
orm PTO-1449 Rev. 7-80)	IM P10-1449 U.S. Department of Commerce			ATTY. DOCKET NO. 033700.003 SERIAD NO. 09/519,998					
	INFORMATION DISCLOSURE STATEMENT				APPLICANT Wilber, et al				
ı	(Use several sheets if necessary)				FILING DATE March 6, 2000  defent le le				
	<u> </u>	U.S.	PATENT DO	OCUMENTS		0/20			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
				6	ا د در				
				-	05.1001	19	-		
:					Ku.	ا بھر ا			
				William	CATBAN	ild			
					CE TRAD				
FOREIGN PATENT				DOCUMENTS		,	TD ANGLATION		
•		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
							110 1.0		
_	07	THER INFORMATION (	including au	thor, title, date, pertir	ient page	es, etc.)			
LQW	AU	"Extracorporeal Immunoadsor Method," authored by Michae	l Garkavij, et al.	, featured in Acta Oncologi	<i>ca</i> , Vol. 35	, No. 3, 1996,	pp. 309-312		
	AV	"Evaluation of Extracorporeal Therapeutic Applications of Re Antibody, Immunoconjugates,	adiolabeled Mon	oclonal Antibodies" author	ed by Krist	ina Norrgren,	ostic and et al., featured in		
	AW	Radionuclides in Therapy, edi							
	AX	"Radionuclide Production for the Biosciences," authored by T.J. Ruth, et al., featured in <i>Nucl. Med. Biol.</i> , Vol. 16, No. 4, 1989, pp. 323-336							
	AY	"Biotinidase," authored by Bar		200 1					
IN	AZ	"Animal Biotinidase," authore Fenniae, Vol. 43, 1965, Suppl		oa, featured in Annales Med	dicinae Exp	erimentalis Et	Biologiae		
EXAMINER	^				DATE	CONSIDER	ED		
Lauren (	) Wall					6/8/9			
* Examiner: Initial		ce considered, whether or not citation this form with next communication		e with MPEP 609; Draw line the	hrough citati	on if not in confe	ormance and not		

					PAGE	4	OF	4
Form PTO-1449 U.S. Department of Commerce			ATTY. DOCKET NO. SERIAL NO.					
Form PTO-1449	,	Patent and Trade	1 22 22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			·		
Rev. 7-80)	atent and Trademark Office L			APPLICANT		<u> </u>	7	
INFORM	A TION	N DISCLOSURE STATE	MENT	Wilber, et al		4 4	~3	,
IMPORM	AIIO	( DISCEOUGHE STATE		FILING DATE		GROUP	7	<b>A</b> .
(	Use sev	veral sheets if necessary)		March 6, 2000		1616 11	(92	O'
			PATENT DO	OCUMENTS		160	/	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASSE	FILING APPRO	DATE IF PRIATE
					PE	JCgg		
					Φ	m 14		
					05	Do la		
					JAH	ليبغ		
					W. T. C.	CINE	-	
					WERT	BARK		
		FOREI	CN PATENT	T DOCUMENTS				
	FOREIGNTATEN				[	GVID GV 4 GG	TRANS	LATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							<u> </u>	
					<del>-</del>			
					1			
			· - · -					
		DITED DIEODMATION	in alreding on	than title data parti	nont nag	os etc)	<u> </u>	
	<u> </u>	THER INFORMATION ( "Plasma Stability and Pharmac	including au	thor, title, date, perti	Riotin Deriv	atives " author	ed by Sco	ntt F
LQW	BA	Rosebrough., featured in <i>The J</i> 408-415	Journal of Pharm	nacology and Experimenta	al Therapeu	tics, Vol. 265	, No. 1, 1	993, pp.
	BB	"Scientific Papers - Proceeding Medicine, Vol. 33, No. 5, May	gs of the 39 <sup>th</sup> And , 1992, pp. 862-	nual Meeting (Wednesday) 864	)," featured	in <i>The Journa</i>	l of Nucle	ear
	BC	"Immunology," featured in Pro	oceedings of AA	CR, Vol. 28, March 1987,	p. 391			
		"Decreased renal accumulation	of biotinylated	chimeric monoclonal antib	ody-neocar	zionostatin cor	jugate af	ter
	BD	administration of avidin", auth 1998, p. 1					<u> </u>	
Mow	BE	"Radiolabeling of Monoclonal 1991, pp. 427-463	Antibodies with	n Metal Chelates," featured	l in Pure &	Appl. Chem, V	Vol. 63, N	o. 3,
EXAMINER	<u> </u>	<u> </u>			DATE CON	SIDERED		
	un (J.	Weller			6,	18/01		
*Examiner Initial if	reference	considered, whether or not citation i	s in conformance	with MPEP 609; Draw line th			mance and	not
		s form with next communication to a		,				

,

					PAGE	· <u>1</u>	OF <u>3</u>
Form PTO-144 (Rev. 7-80)	.9	U.S. Department o		1			
,	N DISCLOSURE STATE	APPLICANT Wilber, et al					
						GROUP	
	(Use se	everal sheets if necessary)	March 6, 2000	· ·	1616 16	19	
. Division of the control of the con		U.S.	PATENT D	OCUMENTS		1	FILING DATE IF
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	APPROPRIATE
FFE	A	5,474,772	12/1995	Maddock			RECEIVE
70 %	<u> </u>	<b>.</b>					- OCI VE
OCT 1 7 2000	<del>2</del> \						OCT 1.0 2
3 001 17	<u> </u>						TO EL
TE TRADEMARK	7						TECH CENTER 16000 900
RADEMA	<u>.</u>	FOREIG	CN DATENT	T DOCUMENTS			9000
		TOKEN	GNIAILN	DOCUMENTS			TRANSLATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
LOW	В	EP 0 567 514 B1	11/1993	Europe			V
1	С	WO91/01749	02/1991	PCT			V
1.00	D	AU-B-64268/90	03/1991	Australia			V
			·				
	0	THER INFORMATION (i	including au	thor, title, date, pertin	ent page	es, etc.)	
Law	Е	"Radioimmunoscintigraphy wit authored by M. Granowska, et a 483-489					
	F	"Radioimaging of Melanoma U Antigen," authored by Lamk M 908s					
	G	"Clinical Studies of Cancer Rac Fragments Labeled with <sup>123</sup> I or (Suppl.), 50, February 1, 1990,	99mTC," authore				
	Н	"Clinical Experience with Iodin Journal of Nuclear Medicine, V	e-123-Iodopher			ames Corbett,	featured in The
	I	"Preliminary Report of an Ongo Phenylpentadecanoic Acid for the Journal of Nuclear Medicine, N	oing Phase I/II I he Identification	Dose Range, Safety and Effic of Viable Myocardium," a	cacy Study uthored by		
	J	"Localization of Cognitive Open Science, Vol. 240, June 17, 198	rations in the H	ıman Brain," authored by M		Posner, et al., fe	eatured in
Läw	K	"Cardiac SPECT with Iodine-12 by F.F. (Russ) Knapp, et al., fea	23-Labeled Fatt	y Acids: Evaluation of Myo		,	•
EXAMINER						CONSIDER	
	Kau	en G. Walla				(e/8/01	
		ce considered, whether or not citation f this form with next communication to		e with MPEP 609; Draw line th	rough citation	on if not in confe	ormance and not

			-	,	PAGE	2	OF <u>3</u>		
Form PTO-1449 U.S. Department of Commerce			ATTY. DOCKET NO. SERIAL NO.						
	(Rev. 7-80) Patent and Trademark Office								
			APPLICANT	•	` ,				
INFORM	[ATIO]	N DISCLOSURE STATE	MENT	Wilber, et al					
				FILING DATE		GROUP			
	(Use se	everal sheets if necessary)	PATENT DO	March 6, 2000		1616 16	લ		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE II APPROPRIATE		
INITIAL									
OIPE	7								
/	<del>8</del> /								
C OCT 1 7 2000	빙								
B	H								
Ve	9								
BADENA	L	FOREI	GN PATENT	DOCUMENTS		<u> </u>			
-							TRANSLATION		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES NO		
							-		
· · · · · · · · · · · · · · · · · · ·	O'	THER INFORMATION (	including aut	thor, title, date, per	tinent page	es, etc.)			
		"Phase I/II Clinical Radioimm	unotherapy with	an Iodine-131-Labeled	Anti-Carcinoe	mbryonic Anti	gen Murine		
LQW	L	Monoclonal Antibody IgG," authored by Thomas M. Behr, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol.							
		38, No. 6 June, 1997, pp. 858- "Phase I Radioimmunotherapy		e-131-CC49 in Metastat	tic Colon Care	inoma." autho	red by C.R.		
	M	Divgi, et al., featured in <i>The Jo</i>							
		"Yttrium-90/Indium-111-DOT							
	N	with Incurable Breast Cancer,"	authored by Sal	ly J. Denardo, et al., feat	tured in <i>Antice</i>	ancer Researc	h, Vol. 17, 1997,		
		pp. 1735-1744 "Experimental Radiotherapy of	Receptor-Positi	ve Human Prostate Ade	nocarcinoma \	With 188Re-RC	-160. A Directly-		
	0	Radiolabeled Somatostatin Ana	alogue," authore	d by Paul O. Zamora, et	al., featured in	n Int. J. Cance	r, Vol. 65, 1996,		
		pp. 214-220				~			
	P	"Regulation of Tumor Cell Gro Somatostatin-Receptor-Mediate							
	Г	57 (suppl 1), 1996, pp. 17-21	cd Radiodiciapy	of Cancer, audiored by	D. Stolz, Ct a	i., icatarca iii i	)1g03t1011,		
		"ZD2767, an Improved System for Antibody-directed Enzyme Prodrug Therapy That Results in Tumor Regressions							
	Q	in Colorectal Tumor Xenograpfts," authored by David C. Blakey, et al., featured in Cancer Research, Vol. 56, July							
. ,		15, 1996, pp. 3287-3292 "Clearance of circulating radio	antibodies using	strentavidin or second	antihodies in :	a venograft mo	del " authored D		
w Qu	R	Marshall, et al., featured in Br.			andoodies in	a konografi me	dei, addicioa D.		
EXAMINER	-			-		CONSIDER	ED		
Lu	Sun D. Well			6/8/01					
		ice considered, whether or not citation	n is in conformance	with MPEP 609: Draw lin	e through citati	on if not in confe	ormance and not		
		f this form with next communication		,	<b>5</b>				

OCI 19 SOOD

		· ·	•		PAGE	3	OF <u>3</u>
Form PTO-1449 U.S. Department of Commerce			ATTY. DOCKET NO. SERIAL NO.				
(Rev. 7-80)	10		1 - 2 - 2 - 2 - 2 - 2				
(2007. 7 00)				APPLICANT	-	5 .	
INFORM	ATION	N DISCLOSURE STATE	MENT	Wilber, et al			
			,	FILING DATE		GROUP	
(	Use sev	veral sheets if necessary)		March 6, 2000		1616-16	19
		U.S.	PATENT DO	OCUMENTS			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
							-
OTP	£ /						
	<i>S</i>						
nct 17	2000						
	Į.						
K.	100				<u> </u>		
MADE	MARI	FOREI	<u>GN PATENT</u>	DOCUMENTS	,	T	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SS SUBCLASS	TRANSLATION
		DOCUMENT NUMBER			02		YES NO
					ļ		
	,						
	Ol	THER INFORMATION (	including au	thor, title, date, perti	nent page	es, etc.)	
LQW	S	"Clinical Aspects of Local and in Anticancer Research, Vol.1"	7, 1997, pp. 170	5-1712			
		"Blood Clearance of Radiolabe	led Antibody: E	nhancement by Lactosamir	ation and	reatment with	Biotin-Avidin or
	T	Anti-Mouse IgG Antibodies," a Medicine, Vol. 29, No. 12, Dec			eatured in	The Journal of	Nuclear
		"Improved Characteristics of a	Human B-Gluer	ronidase-Antibody Coning	ate after D	eglycosylation	for Use in
	U	Antibody-Directed Enzyme Pro	drug Therapy,"	authored by Pieter H. J. Ho	uba, et al.,	featured in Bio	oconjugate
		Chem., Vol. 7, No. 5, 1996, pp	. 606-611				
	, ,	"Site-Specific Prodrug Activati	on by Antibody	-B-Lactamase Conjugates: I	Preclinical	Investigation of	f the Efficacy
	V	and Toxicity of Doxorubicin De featured in <i>Bioconjugate Chem</i>			uniorea by	Dainon L. Me	yeı, et ai.,
ikw	w	"Avidin and Streptavidin," autl			thods in En	zymology, Vo	l. 184, 1990, pp.
	X	51-67 "Avidin," authored by N. Mich	ael Green, featu	red in Adv. Prot Chem V	ol 29 197	5. pp. 85-132	
EXAMINER	Λ	Avidili, addicted by N. Mich	aci Giccii, icatu	Too Hillar. 1 for Chem., V	T	CONSIDER	ED
And the second lates to							
•	Juneary Chinese						
		ce considered, whether or not citation this form with next communication to		e with MPEP 609; Draw line t	hrough citati	on if not in conf	ormance and not

